Cargando…

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis

Detalles Bibliográficos
Autores principales:	Kato, Motoyasu, Sasaki, Shinichi, Nakamura, Takahiro, Kurokawa, Kana, Yamada, Tomoko, Ochi, Yusuke, Ihara, Hiroaki, Takahashi, Fumiyuki, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363798/ https://www.ncbi.nlm.nih.gov/pubmed/32669649 http://dx.doi.org/10.1038/s41598-020-69088-7

Ejemplares similares

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
por: Kato, Motoyasu, et al.
Publicado: (2021)

Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study
por: Kato, Motoyasu, et al.
Publicado: (2019)

Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world
por: Kato, Motoyasu, et al.
Publicado: (2023)

Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib
por: Sakamoto, Naho, et al.
Publicado: (2023)

Author Correction: De novo design of RNA-binding proteins with a prion-like domain related to ALS/FTD proteinopathies
por: Mitsuhashi, Kana, et al.
Publicado: (2020)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation
por: Tsutsumi, Takeo, et al.
Publicado: (2019)

Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway
por: Kato, Motoyasu, et al.
Publicado: (2020)

Development of diffuse alveolar damage after initiation of Nijutsuto
por: Kato, Motoyasu, et al.
Publicado: (2016)

Management of skin sarcoidosis with minocycline monotherapy
por: Sasaki, Shinichi, et al.
Publicado: (2019)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Author Correction: Distinction of surgically resected gastrointestinal stromal tumor by near-infrared hyperspectral imaging
por: Sato, Daiki, et al.
Publicado: (2021)

The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex
por: Takei, Satomi, et al.
Publicado: (2020)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

Development of interstitial pneumonia during treatment with eribulin: a case report
por: Nakamura, Kota, et al.
Publicado: (2017)

Author Correction: Dentinogenic effects of extracted dentin matrix components digested with matrix metalloproteinases
por: Okamoto, Motoki, et al.
Publicado: (2020)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases
por: Ito, Yoko, et al.
Publicado: (2019)

Author Correction: Nucleation dynamics of single crystal WS(2) from droplet precursors uncovered by in-situ monitoring
por: Li, Chao, et al.
Publicado: (2020)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Author Correction: Weakly bound molecules as sensors of new gravitylike forces
por: Borkowski, Mateusz, et al.
Publicado: (2020)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

The synergetic effect of sitafloxacin–arbekacin combination in the Mycobacterium abscessus species
por: Watanabe, Junko, et al.
Publicado: (2023)

Author Correction: Association of ketamine use with lower risks of post-intubation hypotension in hemodynamically-unstable patients in the emergency department
por: Ishimaru, Tadayoshi, et al.
Publicado: (2020)

Author Correction: Compatibility of endoclips in the gastrointestinal tract with magnetic resonance imaging
por: Shin, Dong Yeol, et al.
Publicado: (2021)

Author Correction: Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy
por: Mella, Alberto, et al.
Publicado: (2020)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nnoot1sigk6gn0lpm13du1cvta